GNH India Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: GNH India Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $1.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

GNH India Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $1.8M Trade | TransData Nexus

GNH India Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Other Specialist · $1.8M Total Trade · DGFT Verified

GNH India Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $1.8M across 11 products in 3 therapeutic categories. Based on 170 verified export shipments from Indian Customs (DGFT) records, GNH India Pharmaceuticals Limited is the #1 Indian exporter in 1 product including Pembrolizumab. Top exports include Immunoglobulin ($950.0K), Pembrolizumab ($285.3K), Ustekinumab ($240.5K).

GNH India Pharmaceuticals Limited — Export Portfolio & Destination Treemap

GNH India Pharmaceuticals Limited pharmaceutical export portfolio — 11 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is GNH India Pharmaceuticals Limited? — Company Overview & Market Position

GNH India Pharmaceuticals Limited, established on May 11, 2018, is a public limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U51909MH2018PLC309277. Its authorized share capital is ₹25,00,00,000 (₹25 crore), with a paid-up capital of ₹10,15,71,400 (₹10.16 crore).

The company's registered office is located at Unit No. 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Prabhadevi, Mumbai, Maharashtra 400025, India. GNH India Pharmaceuticals Limited specializes in the wholesale trade and commission trade of pharmaceutical products, excluding motor vehicles and motorcycles.

As of March 2026, the company employs between 11 to 50 individuals. GNH India Pharmaceuticals Limited operates a comprehensive product line, supplying over 235,000 medicines, including branded, generic, orphan, and unlicensed drugs.

What Does GNH India Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$950.0K 2

Product Portfolio — Top 11 by Export Value

GNH India Pharmaceuticals Limited exports 11 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$950.0K	19	0.5%	10
2	Pembrolizumab	Advanced Oncology	$285.3K	6	14.8%	1
3	Ustekinumab	Biologics & Immunotherapy	$240.5K	33	18.9%	2
4	Pazopanib	Advanced Oncology	$185.6K	6	2.2%	4
5	Lenvatinib	Advanced Oncology	$65.7K	20	3.1%	5
6	Actinomycin	Advanced Oncology	$53.4K	56	1.8%	5
7	Cabazitaxel	Advanced Oncology	$23.5K	3	0.3%	8
8	Fludarabine	Advanced Oncology	$18.5K	7	0.6%	10
9	Cladribine	Advanced Oncology	$12.5K	6	5.4%	2
10	Carmustine	Advanced Oncology	$8.9K	8	0.0%	10
11	Lomustine	Advanced Oncology	$2.8K	6	2.7%	8

GNH India Pharmaceuticals Limited exports 11 pharmaceutical products across 3 therapeutic categories with a total export value of $1.8M. The company is the #1 Indian exporter in 1 product: Pembrolizumab. The top category is Other (51.4% of portfolio), followed by Advanced Oncology (35.5%), indicating a concentrated portfolio with the top 5 products accounting for 93.5% of total export value.

GNH India Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

GNH India Pharmaceuticals Limited collaborates with manufacturing facilities that are WHO-GMP, US FDA, and UK MHRA approved. These facilities specialize in producing branded generics, vaccines, and neutral label products across multiple therapeutic areas and forms. The company emphasizes compliance with international standards to ensure the quality and safety of its pharmaceutical products.

3Key Leadership

The company's leadership comprises directors Jessica Piyush Gupta, Shwetha Sudarshan Akkela, and Piyush Ashok Gupta. While specific roles and titles are not detailed in the available sources, these individuals are integral to the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does GNH India Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

GNH India Pharmaceuticals Limited's export activities, as per TransData Nexus data, include shipments to various regulated markets, with a total export value of $1.8 million USD across 170 shipments. The company's product portfolio spans 11 products across three therapeutic categories, with a significant presence in the Advanced Oncology category, accounting for 35.5% of exports. Notably, the company holds the #1 market position in Pembrolizumab, with a 14.8% market share. This indicates a strong foothold in oncology therapeutics within these markets.

2Emerging Markets

GNH India Pharmaceuticals Limited's extensive product line, including over 235,000 medicines, positions it to serve emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GSDP and ISO 9001:2015 standards enhances its credibility and facilitates access to these regions. Additionally, its participation in public tenders and direct supply to government hospitals and health departments underscores its commitment to global healthcare accessibility.

3Geographic Strategy

GNH India Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding GNH India Pharmaceuticals Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. However, the company's compliance with international standards, including WHO-GMP, US FDA, and UK MHRA approvals for its manufacturing facilities, indicates a commitment to meeting FDA requirements.

2WHO & EU GMP

GNH India Pharmaceuticals Limited's manufacturing facilities are WHO-GMP certified, ensuring adherence to international quality standards. While specific details regarding EU GMP certificates and EDQM status are not provided, the company's commitment to quality is evident through its compliance with WHO-GMP and ISO 9001:2015 standards.

3CDSCO & Indian Regulatory

The company's manufacturing facilities are licensed by the Indian FDA, indicating compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. However, the company's adherence to WHO-GMP and ISO 9001:2015 standards suggests a commitment to meeting Indian regulatory requirements.

GNH India Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

GNH India Pharmaceuticals Limited operates in a competitive landscape with several key players in the pharmaceutical distribution sector. While specific market share comparisons are not available, the company's extensive product line, including over 235,000 medicines, and its specialization in sourcing and supplying essential, specialty, and hard-to-access medicines, position it as a significant competitor. Its focus on regulatory compliance and timely delivery further enhances its competitive edge.

2Key Differentiators

GNH India Pharmaceuticals Limited's key differentiators include its extensive product line of over 235,000 medicines, encompassing branded, generic, orphan, and unlicensed drugs. The company's specialization in sourcing and supplying essential, specialty, and hard-to-access medicines, along with its commitment to regulatory compliance and timely delivery, sets it apart in the pharmaceutical distribution sector.

3Strategic Position

GNH India Pharmaceuticals Limited's strategic direction focuses on the wholesale trade and commission trade of pharmaceutical products, excluding motor vehicles and motorcycles. The company's extensive product line and specialization in sourcing and supplying essential, specialty, and hard-to-access medicines indicate a commitment to meeting diverse market needs. Its adherence to international standards and regulatory compliance underscores its dedication to quality and global healthcare accessibility.

Buyer Due Diligence Brief — Evaluating GNH India Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

GNH India Pharmaceuticals Limited's track record includes supplying over 235,000 medicines, indicating a substantial export volume and consistency. The company's compliance with international standards, including WHO-GMP and ISO 9001:2015, and its licensing by the Indian FDA, reflect reliability indicators. While specific export volume and consistency metrics are not publicly available, the company's extensive product line and global reach suggest a reliable supply chain.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's FDA facility registrations and approved ANDAs through the FDA's official website.

WHO-GMP Certification: Verify WHO-GMP certification status through the World Health Organization's official website.

EU GMP Certification: Check for EU GMP certificates and EDQM status through the European Directorate for the Quality of Medicines & HealthCare's official website.

Frequently Asked Questions — GNH India Pharmaceuticals Limited

How many pharmaceutical products does GNH India Pharmaceuticals Limited export from India?

GNH India Pharmaceuticals Limited exports 11 pharmaceutical products across 3 therapeutic categories. The top exports are Immunoglobulin ($950.0K), Pembrolizumab ($285.3K), Ustekinumab ($240.5K), Pazopanib ($185.6K), Lenvatinib ($65.7K). Total export value is $1.8M.

What is GNH India Pharmaceuticals Limited's total pharmaceutical export value?

GNH India Pharmaceuticals Limited's total pharmaceutical export value is $1.8M, based on 170 verified shipments recorded in Indian Customs (DGFT) data.

In which products is GNH India Pharmaceuticals Limited the #1 Indian exporter?

GNH India Pharmaceuticals Limited is the #1 Indian exporter in 1 products: Pembrolizumab (14.8% market share).

What therapeutic categories does GNH India Pharmaceuticals Limited cover?

GNH India Pharmaceuticals Limited exports across 3 therapeutic categories. The largest are Other (51.4%, 1 products), Advanced Oncology (35.5%, 9 products), Biologics & Immunotherapy (13.0%, 1 products).

Get Full GNH India Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.